AC591

· Shandong New Time Pharmaceutical Co., LTD

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AC591, covering 2024-12-09 to 2024-12-09. Get the full timeline:

Most recent: Clinical Trial Update: Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy [Phase 2]